KEISUKE KUIDA
Pilots at Appletree Ln, Lexington, MA
License number
Massachusetts A5174957
Issued Date
Mar 2016
Expiration Date
Mar 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
8 Appletree Ln, Lexington, MA 02420
Professional information
Erk-5 Deficient Animals And Methods Of Inhibiting Angiogenesis Through The Inhibition Of Erk-5
US Patent:
2003016, Aug 28, 2003
Filed:
Jun 22, 2001
Appl. No.:
09/888182
Inventors:
Keisuke Kuida - Lexington MA, US
Michael Su - Newton MA, US
Li Wei - Abington MA, US
Michael Su - Newton MA, US
Li Wei - Abington MA, US
International Classification:
A01K067/027, C12N005/06
US Classification:
800/008000, 435/325000
Abstract:
The invention relates to transgenic non-human animals, embryos and isolated cells therefrom that are heterozygous or homozygous for a mutation in the extracellular signal regulated kinase, Erk5, gene. Such animals, embryos and cells express Erk5 at a reduced level or not at all. Analysis of the homozygous embryos demonstrates a lack of vasculature, indicating that Erk-5 plays a role in angiogenesis. Thus, the present invention also relates to methods for temporarily decreasing or eliminating angiogenesis in a mammal by administering an agent which inhibits Erk-5 expression or Erk-5 activity. And the present invention also relates to methods for increasing angiogenesis in a mammal by administering a functional Erk5 gene.
Erk-5 Deficient Animals And Methods Of Inhibiting Angiogenesis Through The Inhibition Of Erk-5
US Patent:
2003009, May 22, 2003
Filed:
Aug 3, 2001
Appl. No.:
09/922584
Inventors:
Keisuke Kuida - Lexington MA, US
Michael Su - Newton MA, US
Li Wei - Evanston IL, US
Michael Su - Newton MA, US
Li Wei - Evanston IL, US
International Classification:
A01K067/027, C12N005/06
US Classification:
800/018000, 800/008000, 435/354000
Abstract:
The invention relates to transgenic non-human animals, embryos and isolated cells therefrom that are heterozygous or homozygous for a mutation in the extracellular signal regulated kinase, Erk5, gene. Such animals, embryos and cells express Erk5 at a reduced level or not at all. Analysis of the homozygous embryos demonstrates a lack of vasculature, indicating that Erk-5 plays a role in angiogenesis. Thus, the present invention also relates to methods for temporarily decreasing or eliminating angiogenesis in a mammal by administering an agent which inhibits Erk-5 expression or Erk-5 activity. And the present invention also relates to methods for increasing angiogenesis in a mammal by administering a functional Erk5 gene.
Caspase-9 Deficient Animals And The Use Thereof
US Patent:
2009020, Aug 13, 2009
Filed:
Dec 7, 2007
Appl. No.:
12/001064
Inventors:
Keisuke Kuida - Lexington MA, US
Richard A. Flavell - Guilford CT, US
Richard A. Flavell - Guilford CT, US
International Classification:
A61K 39/395, A01K 67/027, A01K 67/033, A61K 31/7088, A61P 43/00
US Classification:
800 18, 800 25, 4241461
Abstract:
The invention relates to genetically manipulated animals that are deficient in the expression of Casapse-9, a protein involved in programmed cell death. The invention further relates to methods for preventing specific types of cell death associated with Caspase-9 activation.
Caspase-9 Deficient Animals And The Use Thereof
US Patent:
2004025, Dec 16, 2004
Filed:
Dec 1, 2000
Appl. No.:
09/728173
Inventors:
Keisuke Kuida - Lexington MA, US
Richard Flavell - Guilford CT, US
Richard Flavell - Guilford CT, US
International Classification:
A01K067/027, C12N005/06
US Classification:
800/014000, 800/018000, 435/354000
Abstract:
The invention relates to genetically manipulated animals that are deficient in the expression of Casapse-9, a protein involved in programmed cell death. The invention further relates to methods for preventing specific types of cell death associated with Caspase-9 activation.